Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07326085
Recruiting Not applicable

Pilot Study to Evaluate the Feasibility, Adherence and Acceptance of the MiDiálisis Platform for Patients on PD

NCT07326085 · tracked via the Priya Life Science Spain tracker
Sponsor
Aida Frías González
Phase
Not applicable
Started
2025-07-27
Last updated
2026-01-08

Condition(s) studied

Peritoneal Dialysis (PD)

Investigational drug(s) / intervention(s)

Smart bandSmart scaleMiDialisis AppPatients will install the app during the phase 2.Patients will connect the digital scale.Patients will connect the smartband.

Smart band: During Phase 2, patients will use the smart band continuously throughout the day.

Smart scale: During Phase 2, patients will weigh themselves daily using the scale.

MiDialisis App: Patients will enter daily blood pressure data and information related to their peritoneal dialysis therapy.

Patients will install the app during the phase 2.: Patients will download and begin using the application.

Patients will connect the digital scale.: Patients will connect the digital scale to the application via Bluetooth.

Patients will connect the smartband.: Patients will connect the smartband to the application via Bluetooth.

Study summary

The main goal of this study is to assess whether a mobile phone app called MiDiálisis is practical, easy to use, and well-accepted. The app was developed by the Technical University of Madrid (UPM) and is designed to bring together the clinical data of people with chronic kidney disease who are on peritoneal dialysis. This way, both patients and doctors can access the information at any time.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients over 18 years of age. * Patients with chronic kidney disease who have been on PD for at least 3 months in the same hospital. * Patients with a stable clinical condition during the 3 months prior to entering the study, defined as no unscheduled hospitalizations or major cardiovascular events (myocardial infarction or stroke) during that period. * Availability of a smartphone or tablet and internet access for the patient/caregiver. * Patients who understand the nature of the study and sign the informed consent form. Exclusion Criteria: * Patients with limitations for multifrequency body composition measurement (pacemaker or implantable cardioverter defibrillator wearers, and pregnant women). * Patients who do not routinely use a smartphone or are unfamiliar with the use of mobile applications. * Patients who are scheduled for a living kidney transplant in the next 6 months. * Patients with a life expectancy of less than 6 months. * Patients in a peritoneal ultrafiltration program due to cardiorenal syndrome.

Primary outcome measure(s)

  • Feasibility and adherence — The investigators analized the number of times that patient or caregiver access the MiDialisis app during 8 weeks that the patient would be installed the App in his mobile.
    To assess the feasibility and adherence to the use of MiDiálisis among patients undergoing peritoneal dialysis (PD), defined as the number of times per week that the patient or caregiver accesses the MiDiálisis app.

Trial sites (1)

FacilityCityRegionStatus
Hospital 12 de Octubre Madrid Madrid Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07326085 on ClinicalTrials.gov ↗ ← All trials in Spain